Effect of polyethylene glycol-electrolyte lavage solution on intestinal microflora

Morotomi, Masami; Guillem, José G.; Pocsidio, Joanne; LoGerfo, Paul; Treat, Michael R.; Forde, Kenneth A.; Weinstein, I. Bernard; Watanabe, Itaru; Mutai, Masahiko

doi:10.1128/aem.55.4.1026-1028.1989

Cited by 20 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Essentially, the studies investigating the effect of PEG 3350 on intestinal flora were performed at a high dose, similar to that used for colonic lavage. Some of these studies showed no significant difference between prelavage and postlavage bacterial cultures, 24,25 while Drago et al showed the decreased density of Lactobacillus and increased density of proteobacteria, which is known to cause severe diarrheal attacks. 6 Contrary, rikenellaceae had been shown to decrease in pediatric patients with NAFLD and increased in individuals who had colonic lavage with PEG.…”

Section: Discussionmentioning

confidence: 99%

A novel therapeutic approach to NASH: Both polyethylene glycol 3350 and lactulose reduce hepatic inflammation in C57BL/6J mice

et al. 2021

View full text Add to dashboard Cite

Background. The gut-liver axis is one of the most emphasized topics in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Intestinal microbiota dysbiosis has been shown to be a predictor of disease severity and progression to fatty liver disease. Therefore, research addressing gut-based therapies has become popular. Objectives.To investigate the effect of lactulose and polyethylene glycol 3350 (PEG 3350) in mice with induced obesity and NAFLD at a non-diarrheal dose. Materials and methods.Thirty-six C57BL/6J male mice were divided into 6 groups. The first 2 groups (n = 6 each) were used as an induced obesity model (group A) and NAFLD model (group B) for 8 weeks. The remaining 24 animals were categorized into control diet group, high-fat diet (HFD) group, HFD + lactulose group, and HFD + PEG 3350 group. Serum and liver tissue samples were obtained for biochemical and histopathological analyses, respectively.Results. The HFD + lactulose treatment group displayed a significant decrease in liver weight (1.3 (1.3-1.4) kg compared to 1.8 (1.6-1.9) kg) and NAFLD activity score (NAS) (1.5 (1.0-3.0) compared to 5.0 (4.0-5.0), respectively; p = 0.0043, p = 0.0021) when compared with the HFD group. However, a decrease in body weight (35.0 (34.6-36.0) kg compared to 40.9 (34.7-41.9) kg) and hepatosteatosis (HS) rate (33.3% compared to 100.0%) were not statistically significant (p = 0. 1796, p = 0.0606, respectively). The HFD + PEG 3350 treatment group showed a statistically significant decrease in body weight (32.4 (30.2-33.9) kg compared to 40.9 (34.7-41.9) kg), liver weight (1.5 (1.3-1.5) kg compared to 1.8 (1.6-1.9) kg), HS rate (16.7% compared to 100.0%) and NAS (0.5 (0.0-1.0) compared to 5.0 (4.0-5.0); p = 0.0086, p = 0.0086, p = 0.0151, and p = 0.0021, respectively) when compared with the HFD group.Conclusions. We demonstrated that non-diarrheal dose of lactulose and PEG 3350 reduced hepatic inflammation in mice with induced NAFLD. It was also observed that PEG 3350 decreased HS and body weight. We believe these mechanisms can be utilized as novel therapeutic approaches in NAFLD in prospective human studies.

show abstract

Section: Discussionmentioning

confidence: 99%

A novel therapeutic approach to NASH: Both polyethylene glycol 3350 and lactulose reduce hepatic inflammation in C57BL/6J mice

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Antibiotics are known to modulate the composition of the intestinal microbiota in both quantitative and qualitative terms (Dethlefsen and Relman, 2011; Ianiro et al, 2016), and their therapeutic efficacy has been demonstrated in non-infectious diseases such as IBS and hepatic encephalopathy (Ianiro et al, 2016). In addition to antibiotics, bowel lavage will reduce the number of intestinal bacteria and affect the microbial ecosystem temporarily (Morotomi et al, 1989; Jalanka et al, 2015). Although recent studies have shown that donor microbiota and specific donor-derived strains colonize the recipient after FMT (Jalanka et al, 2016; Li et al, 2016; Allegretti et al, 2019), it remains unclear whether donor strain engraftment is a prerequisite for the therapeutic efficacy of FMT in rCDI.…”

Section: Introductionmentioning

confidence: 99%

Minor Effect of Antibiotic Pre-treatment on the Engraftment of Donor Microbiota in Fecal Transplantation in Mice

et al. 2019

View full text Add to dashboard Cite

Fecal microbiota transplantation (FMT) is an effective therapy for recurrent Clostridioides difficile infection (rCDI) and is also considered a potential treatment for a wide range of intestinal and systemic diseases. FMT corrects the microbial dysbiosis associated with rCDI, and the engraftment of donor microbiota is likely to play a key role in treatment efficacy. For disease indications other than rCDI, FMT treatment efficacy has been moderate. This may be partly due to stronger resilience of resident host microbiota in patients who do not suffer from rCDI. In rCDI, patients typically have undergone several antibiotic treatments prior to FMT, depleting the microbiota. In this study, we addressed the effect of broad-spectrum antibiotics (Ab) as a pre-treatment to FMT on the engraftment of donor microbiota in recipients. We conducted a pre-clinical study of FMT between two healthy mouse strains, Balb/c as donors and C57BL/6 as recipients, to perform FMT within the same species and to mimic interindividual FMT between human donors and patients. Microbiota composition was assessed with high-throughput 16S rDNA amplicon sequencing. The microbiota of Balb/c and C57BL/6 mice differed significantly, which allowed for the assessment of microbiota transplantation from the donor strain to the recipient. Our results showed that Ab-treatment depleted microbiota in C57BL/6 recipient mice prior to FMT. The diversity of microbiota did not recover spontaneously to baseline levels during 8 weeks after Ab-treatment, but was restored already at 2 weeks in mice receiving FMT. Interestingly, pre-treatment with antibiotics prior to FMT did not increase the overall similarity of the recipient’s microbiota to that of the donor’s, as compared with mice receiving FMT without Ab-treatment. Pre-treatment with Ab improved the establishment of only a few donor-derived taxa, such as Bifidobacterium, in the recipients, thus having a minor effect on the engraftment of donor microbiota in FMT. In conclusion, pre-treatment with broad-spectrum antibiotics did not improve the overall engraftment of donor microbiota, but did improve the engraftment of specific taxa. These results may inform future therapeutic studies of FMT.

show abstract

Surgical Treatment of Rectal Cancer

Bleday¹,

Garcia‐Aguilar²

2007

The ASCRS Textbook of Colon and Rectal Surgery

View full text Add to dashboard Cite

Effect of polyethylene glycol-electrolyte lavage solution on intestinal microflora

Cited by 20 publications

References 11 publications

A novel therapeutic approach to NASH: Both polyethylene glycol 3350 and lactulose reduce hepatic inflammation in C57BL/6J mice

A novel therapeutic approach to NASH: Both polyethylene glycol 3350 and lactulose reduce hepatic inflammation in C57BL/6J mice

Minor Effect of Antibiotic Pre-treatment on the Engraftment of Donor Microbiota in Fecal Transplantation in Mice

Surgical Treatment of Rectal Cancer

Contact Info

Product

Resources

About